Can Semen Quality Predict Lifespan? The Danish Data

Semen analysis may reveal more than fertility potential. In a Danish study of 78,284 men evaluated for couple infertility, poorer semen quality tracked with higher all-cause mortality over decades of follow-up. Men with more than 120 million total motile sperm had an estimated life expectancy of 80.3 years, compared with 77.6 years among men with more than 0 to 5 million: a 2.7-year difference.

That is a striking observational signal, not a new longevity test. A poor semen result does not prove that sperm quality shortens life, and no evidence here shows that raising a sperm count adds years. Semen quality may instead reflect health, exposures, and behaviors that affect both reproduction and survival.

A large study with a long view

Priskorn et al.'s 2025 Danish registry cohort linked semen analyses from men assessed for couple infertility between 1965 and 2015 with national mortality records. Researchers followed the men for a median of 23 years, with some followed for as long as 50 years. During follow-up, 8,600 men died.

Every conventional semen measure examined—total motile sperm count, semen volume, sperm concentration, motility, morphology, and total sperm count—showed an inverse relationship with all-cause mortality. Men with lower values generally had higher mortality later in life.

Total motile sperm count produced the most detailed results. In the 59,657 men with adjustment data, the researchers used more than 120 million motile sperm as the reference category. Adjusted hazard ratios for all-cause mortality were 1.39 for azoospermia, 1.61 for more than 0 to 5 million motile sperm, 1.38 for more than 5 to 10 million, 1.27 for more than 10 to 40 million, 1.16 for more than 40 to 80 million, and 1.19 for more than 80 to 120 million.

The study adjusted for age at testing, calendar period, education, and prior diagnosed disease. Its reported figures do not include confidence intervals here, so those numbers alone cannot show the precision of each category-specific estimate. Still, the overall graded pattern is the central finding: in this infertility-clinic population, semen quality carried information about later all-cause mortality.

Semen quality may be a long-horizon marker of male health status. It has not been validated as a measure of biological age, disease risk, or individual lifespan.

Why the finding makes biological sense—and why that complicates it

Sperm production is sensitive to broad physiologic conditions. That makes a relationship with later health plausible, but it also creates a confounding problem. A biomarker can predict an outcome because it reflects upstream damage or disadvantage; it does not need to cause the outcome itself.

Several studies show that semen measures shift with health-related exposures. A 2025 clinical study found that hypophosphatemia was frequent among infertile men and associated with low motile sperm count. That study does not address mortality, but it supports the idea that sperm measures can track metabolic or endocrine disturbance.

Environmental exposures tell a similar story. A Danish study associated prenatal airborne PCB exposure with poorer adult male reproductive-health markers. A longitudinal Russian cohort linked peripubertal blood lead levels with later reproductive hormones and semen parameters, while a Chinese cohort associated multi-metal exposure trajectories with sperm parameters and sex hormones. PCB evidence, the lead cohort, and the multi-metal study concern reproductive outcomes, not lifespan. They show that semen quality can register environmental insults at different stages of life.

Stress may matter as well. In men attending a fertility center, Reddy and colleagues examined perceived stress in relation to testicular-function markers. That supports a psychophysiologic route through which general health conditions could influence reproductive measures. It does not establish that stress-driven changes in semen quality predict mortality.

The confounding problem is not a footnote

The Danish cohort adjusted for several important factors, but it did not report adjustment here for smoking, adiposity, alcohol intake, physical activity, diet quality, occupational heat, toxicant exposure, or detailed socioeconomic circumstances. Each could affect both semen quality and long-term health.

For example, a 2026 study of 3,425 men followed for 24 months found that rotating shift work was associated with reduced fecundity, with sperm concentration and vitality accounting for much of that association. Wang et al. did not study mortality, so their result neither confirms nor refutes the Danish finding. It does show that a work-pattern exposure can alter semen measures through pathways that may also influence chronic disease risk.

Diet and toxicant studies make the same causal shortcut unsafe. In men attending fertility clinics, a cross-sectional study associated Mediterranean dietary pattern and lifestyle factors with semen quality. Another cross-sectional study linked urinary organophosphate ester concentrations with semen quality. The diet and lifestyle study and the organophosphate ester study cannot establish cause and effect, but they identify plausible shared causes. Lower semen quality may partly reflect a harmful exposure burden or lifestyle pattern rather than an intrinsic capacity to survive longer.

Can you improve the number, and does that matter?

Semen parameters are modifiable in some settings. That is useful for reproductive care, but it does not close the longevity loop.

A 2025 systematic review and meta-analysis of randomized trials found that alpha lipoic acid improved several sperm parameters in infertile men. The alpha lipoic acid review tested sperm-related outcomes, not morbidity or mortality. Its result cannot tell us whether changing those parameters changes health outside fertility treatment.

A separate 2025 systematic review and meta-analysis associated Mediterranean diet adherence with better semen quality and medically assisted reproduction outcomes in men. That evidence is encouraging for reproductive outcomes, yet much of the diet evidence is observational and none of it demonstrates longer survival through improved semen quality.

In idiopathic male infertility, a network meta-analysis of 24 controlled studies involving 1,676 men found that empirical hormonal treatments, including antiestrogens and FSH, improved selected semen and fertility outcomes. Santi et al. evaluated sperm concentration, total sperm number, progressive motility, and fertility-related outcomes—not lifespan. A better surrogate is not automatically a better patient outcome. Medicine has learned that lesson often enough to keep it on speed dial.

Who does this apply to?

The Danish cohort included men assessed because of couple infertility. It was not a population-based sample of all Danish men, much less all men worldwide. The association may differ in fertile men, younger people seeking direct-to-consumer testing, people outside specialty care, and populations with different social conditions, healthcare systems, or environmental exposures.

The azoospermia group also included different underlying conditions; the reported summary does not separate obstructive from non-obstructive azoospermia. Those conditions can have very different causes and health implications. The study also does not establish which causes of death drove the association or a semen threshold that should trigger cardiovascular, cancer, or other medical screening.

What to do with an abnormal semen analysis

A semen analysis remains a reproductive test first. It can also be a reasonable prompt to review broader health factors with a clinician: sleep and shift-work demands, smoking, alcohol, weight, diet, medications, occupational heat, and possible toxicant exposures. That review makes sense because those factors affect health regardless of whether sperm measures predict lifespan.

Do not use a home semen test or a fertility-clinic result to calculate your biological age. The best available evidence shows a meaningful association between poorer semen quality and shorter lifespan in one large clinic-based cohort. It does not show that semen quality causes longevity, that supplements extend life by improving sperm measures, or that a semen analysis can replace ordinary preventive care.